Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


25.02.2019

1 AJR Am J Roentgenol
1 Am J Clin Oncol
1 BJU Int
2 Cancer Lett
7 Eur Urol
2 Int J Cancer
1 J Clin Oncol
1 Nat Rev Urol
1 Oncogene
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. CHOI MH, Kim CK, Lee YJ, Jung SE, et al
    Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study.
    AJR Am J Roentgenol. 2019 Feb 19:1-8. doi: 10.2214/AJR.18.20498.
    PubMed     Text format     Abstract available


    Am J Clin Oncol

  2. STEIN MN, Chen YH, Carducci MA, Hudes GR, et al
    Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805).
    Am J Clin Oncol. 2019 Feb 15. doi: 10.1097/COC.0000000000000526.
    PubMed     Text format     Abstract available


    BJU Int

  3. LOPCI E, Piccardo A, Lazzeri M
    Prostate cancer imaging and therapeutic alternatives with highly specific molecular "probes".
    BJU Int. 2019 Feb 20. doi: 10.1111/bju.14713.
    PubMed     Text format     Abstract available


    Cancer Lett

  4. GESMUNDO I, Di Blasio L, Banfi D, Villanova T, et al
    Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3beta signaling and inhibition of cellular prostatic acid phosphatase.
    Cancer Lett. 2019 Feb 18. pii: S0304-3835(19)30106.
    PubMed     Text format     Abstract available

  5. FOWKE JH, Koyama T, Dai Q, Zheng SL, et al
    Blood and Dietary Magnesium Levels are not linked with lower Prostate Cancer Risk in Black or White Men.
    Cancer Lett. 2019 Feb 15. pii: S0304-3835(19)30101.
    PubMed     Text format     Abstract available


    Eur Urol

  6. THOMPSON JE, Egger S, Bohm M, Siriwardana AR, et al
    Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases.
    Eur Urol. 2018;73:664-671.
    PubMed     Text format     Abstract available

  7. KEARNS JT, Faino AV, Newcomb LF, Brooks JD, et al
    Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
    Eur Urol. 2018;73:706-712.
    PubMed     Text format     Abstract available

  8. CONTEDUCA V, Jayaram A, Romero-Laorden N, Wetterskog D, et al
    Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019;75:368-373.
    PubMed     Text format     Abstract available

  9. NABID A, Souhami L
    Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Abdenour Nabid, Nathalie Carrier, Andre-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31
    Eur Urol. 2019;75:e63.
    PubMed     Text format    

  10. PERERA M, Papa N, Roberts M, Williams M, et al
    Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and M
    Eur Urol. 2019 Feb 14. pii: S0302-2838(19)30095.
    PubMed     Text format     Abstract available

  11. SHORT CE, Trinh L, James EL
    Effective Technology-based Behaviour Change Interventions in Prostate Cancer Supportive Care: Are We There Yet?
    Eur Urol. 2019 Feb 15. pii: S0302-2838(19)30109.
    PubMed     Text format    

  12. LEONGAMORNLERT DA, Saunders EJ, Wakerell S, Whitmore I, et al
    Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
    Eur Urol. 2019 Feb 15. pii: S0302-2838(19)30096.
    PubMed     Text format     Abstract available


    Int J Cancer

  13. HUANG J, Mondul AM, Weinstein SJ, Derkach A, et al
    Prospective Serum Metabolomic Profiling of Lethal Prostate Cancer.
    Int J Cancer. 2019 Feb 18. doi: 10.1002/ijc.32218.
    PubMed     Text format     Abstract available

  14. GRAF ME, Sookthai D, Johnson T, Schubel R, et al
    Pre-diagnostic plasma concentrations of Fibrinogen, sGPIIb/IIIa, sP-selectin, sThrombomodulin, Thrombopoietin in relation to cancer risk: Findings from a large prospective study.
    Int J Cancer. 2018;143:2659-2667.
    PubMed     Text format     Abstract available


    J Clin Oncol

  15. VAPIWALA N, Hofman MS, Murphy DG, Williams S, et al
    Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart.
    J Clin Oncol. 2019 Feb 22:JCO1801927. doi: 10.1200/JCO.18.01927.
    PubMed     Text format    


    Nat Rev Urol

  16. FENNER A
    Prostate cancer: a tale of two sides.
    Nat Rev Urol. 2019 Feb 18. pii: 10.1038/s41585-019-0152.
    PubMed     Text format    


    Oncogene

  17. LIAO CP, Lin TP, Li PC, Geary LA, et al
    Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.
    Oncogene. 2018 May 29. pii: 10.1038/s41388-018-0325.
    PubMed     Text format     Abstract available


    Urology

  18. EINSTEIN DJ, Patil D, Chipman J, Regan MM, et al
    Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life after Treatment for Localized Prostate Cancer.
    Urology. 2019 Feb 18. pii: S0090-4295(19)30152.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: